Hyderabad: The Drugs Controller General of India (DGCI) has given permission to Bharat Biotech to test its COVID-19 vaccine, COVAXIN, by administering it via the skin.
This intradermal vaccine delivery route is less invasive and will require a lesser dosage as well. The inactive virus-based vaccine is also being tested to be delivered in the intramuscular way.
Currently, the indigenously built vaccine is in phase II trials.
Comments are closed.